JPH09509663A - 新規ホスホルアミデートおよびホスホロチオアミデートオリゴマー化合物 - Google Patents
新規ホスホルアミデートおよびホスホロチオアミデートオリゴマー化合物Info
- Publication number
- JPH09509663A JPH09509663A JP7522463A JP52246395A JPH09509663A JP H09509663 A JPH09509663 A JP H09509663A JP 7522463 A JP7522463 A JP 7522463A JP 52246395 A JP52246395 A JP 52246395A JP H09509663 A JPH09509663 A JP H09509663A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- group
- alkyl
- carbon atoms
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 177
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 title description 58
- RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 title description 40
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 19
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000001301 oxygen Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 168
- -1 methoxytrityl Chemical group 0.000 claims description 94
- 239000007787 solid Substances 0.000 claims description 69
- 150000001412 amines Chemical group 0.000 claims description 53
- 125000004432 carbon atom Chemical group C* 0.000 claims description 39
- 108091034117 Oligonucleotide Proteins 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
- 125000006239 protecting group Chemical group 0.000 claims description 24
- 239000002253 acid Chemical group 0.000 claims description 21
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 18
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 15
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 15
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 13
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 150000004713 phosphodiesters Chemical class 0.000 claims description 11
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 8
- 229960000643 adenine Drugs 0.000 claims description 8
- 229940104302 cytosine Drugs 0.000 claims description 8
- 229930024421 Adenine Natural products 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 229920000570 polyether Chemical group 0.000 claims description 7
- 125000006853 reporter group Chemical group 0.000 claims description 7
- 229940113082 thymine Drugs 0.000 claims description 7
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004721 Polyphenylene oxide Chemical group 0.000 claims description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 150000003573 thiols Chemical group 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 4
- 150000003212 purines Chemical group 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 3
- 125000006242 amine protecting group Chemical group 0.000 claims description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 3
- 230000001268 conjugating effect Effects 0.000 claims description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 3
- 150000003235 pyrrolidines Chemical class 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 claims description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 3
- 229940045145 uridine Drugs 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 abstract description 61
- 238000003786 synthesis reaction Methods 0.000 abstract description 47
- 230000015572 biosynthetic process Effects 0.000 abstract description 45
- 238000007254 oxidation reaction Methods 0.000 abstract description 29
- 230000003647 oxidation Effects 0.000 abstract description 27
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 abstract description 14
- 238000010168 coupling process Methods 0.000 abstract description 12
- 230000008878 coupling Effects 0.000 abstract description 10
- 238000005859 coupling reaction Methods 0.000 abstract description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 2
- 239000005864 Sulphur Chemical group 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 89
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 84
- 239000000243 solution Substances 0.000 description 76
- 239000011347 resin Substances 0.000 description 58
- 229920005989 resin Polymers 0.000 description 58
- 239000000203 mixture Substances 0.000 description 53
- 239000005289 controlled pore glass Substances 0.000 description 51
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 43
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 239000000178 monomer Substances 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- 230000000694 effects Effects 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- 238000009739 binding Methods 0.000 description 24
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 24
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 23
- 150000002148 esters Chemical class 0.000 description 22
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 16
- 150000008298 phosphoramidates Chemical class 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 15
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 125000003277 amino group Chemical group 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- LOSXTWDYAWERDB-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2,3-dimethoxybenzene Chemical compound COC1=CC=CC(C(Cl)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1OC LOSXTWDYAWERDB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000010348 incorporation Methods 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 239000000543 intermediate Substances 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 238000001212 derivatisation Methods 0.000 description 11
- 239000001257 hydrogen Substances 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 10
- BVVCDLLKIBUISQ-UHFFFAOYSA-N acetonitrile;pyridine Chemical compound CC#N.C1=CC=NC=C1 BVVCDLLKIBUISQ-UHFFFAOYSA-N 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical group OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 150000008300 phosphoramidites Chemical class 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 9
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 239000000539 dimer Substances 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 239000000284 extract Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000001590 oxidative effect Effects 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- FUWGSUOSJRCEIV-UHFFFAOYSA-N phosphonothioic O,O-acid Chemical compound OP(O)=S FUWGSUOSJRCEIV-UHFFFAOYSA-N 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- WERYXYBDKMZEQL-UHFFFAOYSA-N 1,4-butanediol Substances OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 7
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 229960005215 dichloroacetic acid Drugs 0.000 description 7
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002777 nucleoside Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 150000003335 secondary amines Chemical class 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 229940014800 succinic anhydride Drugs 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940059260 amidate Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 125000003835 nucleoside group Chemical group 0.000 description 6
- 239000011574 phosphorus Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 229940086735 succinate Drugs 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000000370 acceptor Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 5
- 238000006384 oligomerization reaction Methods 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 150000003141 primary amines Chemical class 0.000 description 5
- 239000001384 succinic acid Substances 0.000 description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 4
- MIBQYWIOHFTKHD-UHFFFAOYSA-N adamantane-1-carbonyl chloride Chemical compound C1C(C2)CC3CC2CC1(C(=O)Cl)C3 MIBQYWIOHFTKHD-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- ZLRAAUUPULJGTL-UHFFFAOYSA-N diaminophosphinous acid Chemical compound NP(N)O ZLRAAUUPULJGTL-UHFFFAOYSA-N 0.000 description 4
- 150000005690 diesters Chemical class 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- FEHUTHGOLLQBNW-UHFFFAOYSA-N n-[chloro-[di(propan-2-yl)amino]phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(Cl)N(C(C)C)C(C)C FEHUTHGOLLQBNW-UHFFFAOYSA-N 0.000 description 4
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 4
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 229940043375 1,5-pentanediol Drugs 0.000 description 3
- YBXJEAPQVULNKE-UHFFFAOYSA-N 1-acetyl-5-methylpyrimidine-2,4-dione Chemical compound CC(=O)N1C=C(C)C(=O)NC1=O YBXJEAPQVULNKE-UHFFFAOYSA-N 0.000 description 3
- TZDMCKHDYUDRMB-UHFFFAOYSA-N 2-(5-methyl-2,4-dioxopyrimidin-1-yl)acetic acid Chemical compound CC1=CN(CC(O)=O)C(=O)NC1=O TZDMCKHDYUDRMB-UHFFFAOYSA-N 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 102000015439 Phospholipases Human genes 0.000 description 3
- 108010064785 Phospholipases Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000001994 activation Methods 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical group CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 3
- 238000006642 detritylation reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000003998 snake venom Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- ZILSBZLQGRBMOR-UHFFFAOYSA-N 1,3-benzodioxol-5-ylmethanamine Chemical compound NCC1=CC=C2OCOC2=C1 ZILSBZLQGRBMOR-UHFFFAOYSA-N 0.000 description 2
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- PNHGJPJOMCXSKN-UHFFFAOYSA-N 2-(1-methylpyrrolidin-2-yl)ethanamine Chemical compound CN1CCCC1CCN PNHGJPJOMCXSKN-UHFFFAOYSA-N 0.000 description 2
- MXLMTQWGSQIYOW-UHFFFAOYSA-N 3-methyl-2-butanol Chemical compound CC(C)C(C)O MXLMTQWGSQIYOW-UHFFFAOYSA-N 0.000 description 2
- 238000004679 31P NMR spectroscopy Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- LQVMZVKOVPITOO-UHFFFAOYSA-N 9h-fluoren-1-ylmethyl carbonochloridate Chemical compound C1C2=CC=CC=C2C2=C1C(COC(=O)Cl)=CC=C2 LQVMZVKOVPITOO-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- RGVCLMWHXYTBJC-UHFFFAOYSA-N NP(O)(O)=O.NP(O)(O)=O.NP(O)(O)=O.N.N Chemical compound NP(O)(O)=O.NP(O)(O)=O.NP(O)(O)=O.N.N RGVCLMWHXYTBJC-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- DXMPMKSMHQNXSC-UHFFFAOYSA-N adamantane;carbonyl dichloride;dipropan-2-yl hydrogen phosphite Chemical compound ClC(Cl)=O.CC(C)OP(O)OC(C)C.C1C(C2)CC3CC1CC2C3 DXMPMKSMHQNXSC-UHFFFAOYSA-N 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- UOKRBSXOBUKDGE-UHFFFAOYSA-N butylphosphonic acid Chemical compound CCCCP(O)(O)=O UOKRBSXOBUKDGE-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- USJRLGNYCQWLPF-UHFFFAOYSA-N chlorophosphane Chemical compound ClP USJRLGNYCQWLPF-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- FOTKYAAJKYLFFN-UHFFFAOYSA-N decane-1,10-diol Chemical compound OCCCCCCCCCCO FOTKYAAJKYLFFN-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- NFORZJQPTUSMRL-UHFFFAOYSA-N dipropan-2-yl hydrogen phosphite Chemical compound CC(C)OP(O)OC(C)C NFORZJQPTUSMRL-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- GATNOFPXSDHULC-UHFFFAOYSA-N ethylphosphonic acid Chemical compound CCP(O)(O)=O GATNOFPXSDHULC-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ZYQPNKHEEHSDCO-UHFFFAOYSA-N n-[[di(propan-2-yl)amino]-ethoxyphosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CCOP(N(C(C)C)C(C)C)N(C(C)C)C(C)C ZYQPNKHEEHSDCO-UHFFFAOYSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000003279 phenylacetic acid Substances 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000003900 succinic acid esters Chemical group 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- QCIDBNKTKNBPKM-UHFFFAOYSA-N trencam-3,2-hopo Chemical compound NC(=O)C1=CC=CC(O)=C1O QCIDBNKTKNBPKM-UHFFFAOYSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
- RFIYMMQERCRRKM-UHFFFAOYSA-N 1-o-(9h-fluoren-9-ylmethyl) 5-o-methyl 4-amino-2-(hydroxymethyl)pentanedioate Chemical compound C1=CC=C2C(COC(=O)C(CO)CC(N)C(=O)OC)C3=CC=CC=C3C2=C1 RFIYMMQERCRRKM-UHFFFAOYSA-N 0.000 description 1
- LEUCVRSDXZZLGS-UHFFFAOYSA-N 10-[(2,3-dimethoxyphenyl)-diphenylmethoxy]decan-1-ol Chemical compound COC1=CC=CC(C(OCCCCCCCCCCO)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1OC LEUCVRSDXZZLGS-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- OWEMTCOXFULTNW-UHFFFAOYSA-N 2,3-dimethyl-2-propan-2-ylbutanoic acid Chemical compound CC(C)C(C)(C(C)C)C(O)=O OWEMTCOXFULTNW-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- PYBVXNWDSBYQSA-UHFFFAOYSA-N 2-aminobutane-1,4-diol Chemical compound OCC(N)CCO PYBVXNWDSBYQSA-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- UEDDHBVGNLVMRQ-UHFFFAOYSA-N 2-aminopentane-1,5-diol Chemical compound OCC(N)CCCO UEDDHBVGNLVMRQ-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- PPVIGLHWNQLEQO-UHFFFAOYSA-N 3-methoxyheptan-4-one Chemical compound CCCC(=O)C(CC)OC PPVIGLHWNQLEQO-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- VUTBELPREDJDDH-UHFFFAOYSA-N 4-amino-5-hydroxymethyl-2-methylpyrimidine Chemical compound CC1=NC=C(CO)C(N)=N1 VUTBELPREDJDDH-UHFFFAOYSA-N 0.000 description 1
- SJILKDPNOANEEJ-UHFFFAOYSA-N 4-decoxy-4-oxobutanoic acid Chemical compound CCCCCCCCCCOC(=O)CCC(O)=O SJILKDPNOANEEJ-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- SSPYSWLZOPCOLO-UHFFFAOYSA-N 6-azauracil Chemical compound O=C1C=NNC(=O)N1 SSPYSWLZOPCOLO-UHFFFAOYSA-N 0.000 description 1
- RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 1
- NEHZDXMOBCKLTJ-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(1,3-dihydroxypropan-2-yl)carbamate Chemical compound C1=CC=C2C(COC(=O)NC(CO)CO)C3=CC=CC=C3C2=C1 NEHZDXMOBCKLTJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001436679 Adama Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000040710 Chela Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- IVHVNMLJNASKHW-UHFFFAOYSA-M Chlorphonium chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CC1=CC=C(Cl)C=C1Cl IVHVNMLJNASKHW-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- MDCTVRUPVLZSPG-BQBZGAKWSA-N His-Asp Chemical group OC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CNC=N1 MDCTVRUPVLZSPG-BQBZGAKWSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ZGEYCCHDTIDZAE-BYPYZUCNSA-N L-glutamic acid 5-methyl ester Chemical compound COC(=O)CC[C@H](N)C(O)=O ZGEYCCHDTIDZAE-BYPYZUCNSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 229930184725 Lipoxin Natural products 0.000 description 1
- 102000011720 Lysophospholipase Human genes 0.000 description 1
- 108020002496 Lysophospholipase Proteins 0.000 description 1
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 1
- 101800000021 N-terminal protease Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- MJXTVYZXUHNQKX-UHFFFAOYSA-N NP(O)(O)=O.NCc1ccccc1 Chemical compound NP(O)(O)=O.NCc1ccccc1 MJXTVYZXUHNQKX-UHFFFAOYSA-N 0.000 description 1
- SEFSHGZTTCMOHS-UHFFFAOYSA-N NP(O)(O)=O.OP(O)(O)=S.OP(O)(O)=S Chemical compound NP(O)(O)=O.OP(O)(O)=S.OP(O)(O)=S SEFSHGZTTCMOHS-UHFFFAOYSA-N 0.000 description 1
- ITSMBYHGHYTIDZ-UHFFFAOYSA-N NP(O)(O)=S.NP(O)(O)=S.NP(O)(O)=S.N.N Chemical compound NP(O)(O)=S.NP(O)(O)=S.NP(O)(O)=S.N.N ITSMBYHGHYTIDZ-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 229910004679 ONO2 Inorganic materials 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 description 1
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 description 1
- 108090000553 Phospholipase D Proteins 0.000 description 1
- 102000011420 Phospholipase D Human genes 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 239000004952 Polyamide Chemical group 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-M Thiocarbamate Chemical compound NC([S-])=O GNVMUORYQLCPJZ-UHFFFAOYSA-M 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 244000085553 Triticum polonicum Species 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003659 bee venom Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- KDPAWGWELVVRCH-UHFFFAOYSA-N bromoacetic acid Chemical compound OC(=O)CBr KDPAWGWELVVRCH-UHFFFAOYSA-N 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- FQINETJTVSEXPE-UHFFFAOYSA-N butanedioic acid;butane-1,4-diol Chemical compound OCCCCO.OC(=O)CCC(O)=O FQINETJTVSEXPE-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000001369 canonical nucleoside group Chemical group 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- WDJQAYUPVJEQJW-UHFFFAOYSA-N chloroform;n,n-diethylethanamine;methanol Chemical compound OC.ClC(Cl)Cl.CCN(CC)CC WDJQAYUPVJEQJW-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 125000000332 coumarinyl group Chemical class O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 101150008740 cpg-1 gene Proteins 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DMSZORWOGDLWGN-UHFFFAOYSA-N ctk1a3526 Chemical compound NP(N)(N)=O DMSZORWOGDLWGN-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- AISZOMRXKKCPIS-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioylsulfanylacetate Chemical compound CCOC(=O)CSP(=S)(OCC)OCC AISZOMRXKKCPIS-UHFFFAOYSA-N 0.000 description 1
- ZJXZSIYSNXKHEA-UHFFFAOYSA-N ethyl dihydrogen phosphate Chemical compound CCOP(O)(O)=O ZJXZSIYSNXKHEA-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- VUERQRKTYBIULR-UHFFFAOYSA-N fosetyl Chemical compound CCOP(O)=O VUERQRKTYBIULR-UHFFFAOYSA-N 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 102000045360 human SDHB Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KCWDJXPPZHMEIK-UHFFFAOYSA-N isocyanic acid;toluene Chemical compound N=C=O.N=C=O.CC1=CC=CC=C1 KCWDJXPPZHMEIK-UHFFFAOYSA-N 0.000 description 1
- 238000010501 iterative synthesis reaction Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002639 lipoxins Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- PQSOLLURQXDZSZ-UHFFFAOYSA-N n,n-diethylethanamine;ethyl acetate;methanol Chemical compound OC.CCOC(C)=O.CCN(CC)CC PQSOLLURQXDZSZ-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- PUVGJZNCQUWSCO-UHFFFAOYSA-N n-[butoxy-[di(propan-2-yl)amino]phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CCCCOP(N(C(C)C)C(C)C)N(C(C)C)C(C)C PUVGJZNCQUWSCO-UHFFFAOYSA-N 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 150000002815 nickel Chemical class 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 1
- 125000001893 nitrooxy group Chemical group [O-][N+](=O)O* 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- REJGOFYVRVIODZ-UHFFFAOYSA-N phosphanium;chloride Chemical compound P.Cl REJGOFYVRVIODZ-UHFFFAOYSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000003358 phospholipase A2 inhibitor Substances 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 125000005543 phthalimide group Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- QVLTXCYWHPZMCA-UHFFFAOYSA-N po4-po4 Chemical compound OP(O)(O)=O.OP(O)(O)=O QVLTXCYWHPZMCA-UHFFFAOYSA-N 0.000 description 1
- 229920002647 polyamide Chemical group 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 125000001107 pteroylglutamyl group Chemical group 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- XSOKHXFFCGXDJZ-UHFFFAOYSA-N telluride(2-) Chemical compound [Te-2] XSOKHXFFCGXDJZ-UHFFFAOYSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Luminescent Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 下記の構造の化合物: [式中 各々のXは独立してOまたはSであり; 各々のYは[Q2]j−Z2であり; 各々のTは独立して[Q1]k−Z1であるか、またはYおよびTが一緒に窒素 へテロ環に組み込まれ; Q1、Q2および各々のLは独立してC2−C10アルキル、C2−C10アルケニル 、C2−C10アルキニル、C4−C7炭素環−アルキルまたは−アルケニル、ヘテ ロ環、2から10の炭素原子を有しおよび1から4の酸素または硫黄原子を有す るエーテル、ポリアルキレングリコール、またはC7−C14アラルキルであり、 Lがヘテロ環である場合は少なくとも一つのLは置換ピロリジンまたは天然の核 塩基ではなく、およびLがアルキルの場合は少なくとも一つのLは置換グリコー ルではない; E1およびE2は独立してH、ヒドロキシル保護基、活性化固体支持体、コンジ ュゲート基、レポーター基、ポリエチレングリコール、アルキル、オリゴヌクレ オチド、ペプチド核酸、ホスフェート、ホスファイト、活性化ホスフェートまた は活性化ホスファイトであり; jおよびkは独立して0または1であり; mは2から約50であり; Z1およびZ2は独立して、H、C1−C2アルキル、C2−C20アルケニル、C2 −C20アルキニル、C6−C14アリール、C7−C15アラルキル、ハロゲン、CH =O、OR1、SR2、NR3R4、C(=NH)NR3R4、CH(NR3R4)、N HC(=NH)NR3R4、CH(NH2)C(=O)OH、C(=O)NR3R4 、C(=O)OR5、金属配位基、レポーター基、窒素含有ヘテロ環、プリン、 ピリミジン、ホスフェート基、ポリエーテル基、またはポリエチレングリコール 基であり; AはL1、L1−G1、L2、L2−G2、NR3R4、H、窒素含有ヘテロ環、プリ ン、ピリミジン、ホスフェート基、ポリエーテル基、またはポリエチレングリコ ール基であり; JはL1、G3、L1−G3、またはG3−L1−G3であり; L1は1から約20の炭素原子を有するアルキル、2から約20の炭素原子を 有するアルケニル、または2から約20の炭素原子を有するアルキニルであり; L2は6から約14の炭素原子を有するアリールまたは7から15の炭素原子 を有するアラルキルであり; G1はハロゲン、OR1、SR2、NR3R4、C(=NH)NR3R4、NHC( =NH)NR3R4、CH=O、C(=O)OR5、CH(NR3R4)(C(=O )OR5)、C(=O)NR3R4、金属配位基、またはホスフェート基であり; G2はハロゲン、OH、SH、SCH3、またはNR3R4であり; G3はC(=O)、C(=S)、C(O)−O、C(O)−NH、C(S)− O、C(S)−NHまたはS(O)2であり; 各々のd1は独立して0または1であり; 各々のd2は独立して0から6であり; 各々のd3は独立して1から6であり; R1はH、1から約6の炭素原子を有するアルキル、またはヒドロキシル保護 基であり; R2はH、1から約6の炭素原子を有するアルキル、またはチオール保護基で あ り; R3およびR4は独立してH、1から約6の炭素原子を有するアルキル、または アミン保護基であり;および R5はH、1から約6の炭素原子を有するアルキル、または酸保護基である] 。 2. Lが約2から約10の炭素を有するアルキルである請求項1に記載の化 合物。 3. YおよびTが一緒に窒素ヘテロ環に組み込まれている請求項1に記載の 化合物。 4. 前記ヘテロ環がピペリジンまたはビロリジンである請求項3に記載の化 合物。 5. E1がH、ヒドロキシル保護基、または活性化固体支持体である請求項 1に記載の化合物。 6. E2がトリチル、メトキシトリチル、ジメトキシトリチルまたはトリメ トキシトリチルである請求項1に記載の化合物。 7. E2がHまたはヒドロキシル保護基である請求項1に記載の化合物。 8. Z2がHである請求項1に記載の化合物。 9. Z1がプリンまたはピリミジンである請求項1に記載の化合物。 10. Z1がアデニン、グアニン、シトシン、ウリジンまたはチミンである請 求項9に記載の化合物。 11. Z1が1から約20の炭素原子を有するアルキルである請求項1に記載 の化合物。 12. Z1が6から約14の炭素原子を有するアリールまたは7から約15の 炭素原子を有するアラルキルである請求項1に記載の化合物。 13. Z1がフルオレニルメチル、フェニル、またはベンジルである請求項1 に記載の化合物。 14. Z1がポリエチレングリコールまたはグルタミルである請求項1に記載 の化合物。 15. mが約2から約25である請求項1に記載の化合物。 16. XがOである請求項1に記載の化合物。 17. XがSである請求項1に記載の化合物。 の化合物。 20. 少なくとも一つの前記L基が他の前記L基と異なっている請求項1に記 載の化合物。 21. ホスホジエステルまたはホスホロチオエートオリゴヌクレオチドを含む 第一の領域および下記の構造を有する第二の領域を有するキメラオリゴマー化合 物: [式中 各々のXは独立してOまたはSであり; 各々のYは[Q2]j−Z2であり; 各々のTは独立して[Q1]k−Z1であるか、またはYおよびTが一緒に窒素 へテロ環に組み込まれ; Q1、Q2および各々のLは独立してC2−C10アルキル、C2−C10アルケニル 、 C2−C10アルキニル、C4−C7炭素環−アルキルまたは−アルケニル、ヘテロ 環、2から10の炭素原子を有しおよび1から4の酸素または硫黄原子を有する エーテル、ポリアルキレングリコール、またはC7−C14アラルキルであり、L がヘテロ環である場合は少なくとも一つのLは置換ピロリジンまたは天然の核塩 基ではなく、およびLがアルキルの場合は少なくとも一つのLは置換グリコール ではない; E1およびE2の一つがホスホジエステルまたはホスホロチオエートオリゴヌク レオチドを含む前記第一の領域であり、および前記E1およびE2の他方がH、ヒ ドロキシル保護基、活性化固体支持体、コンジュゲート基、レポーター基、ポリ エチレングリコール、アルキル、オリゴヌクレオチド、ペプチド核酸、ホスフェ ート、ホスファイト、活性化ホスフェートまたは活性化ホスファイトであり; jおよびkは独立して0または1であり; mは2から約50であり; Z1およびZ2は独立して、H、C1−C2アルキル、C2−C20アルケニル、C2 −C20アルキニル、C6−C14アリール、C7−C15アラルキル、ハロゲン、CH =O、OR1、SR2、NR3R4、C(=NH)NR3R4、CH(NR3R4)、N HC(=NH)NR3R4、CH(NH2)C(=O)OH、C(=O)NR3R4 、C(=O)OR5、金属配位基、レポーター基、窒素含有ヘテロ環、プリン、 ピリミジン、ホスフェート基、ポリエーテル基、またはポリエチレングリコール 基であり; AはL1、L1−G1、L2、L2−G2、NR3R4、H、窒素含有ヘテロ環、プリ ン、ピリミジン、ホスフェート基、ポリエーテル基、またはポリエチレングリコ ール基であり: JはL1、G3、L1−G3、またはG3−L1−G3であり; L1は1から約20の炭素原子を有するアルキル、2から約20の炭素原子を 有するアルケニル、または2から約20の炭素原子を有するアルキニルであり; L2は6から約14の炭素原子を有するアリールまたは7から15の炭素原子 を有するアラルキルであり; G1はハロゲン、OR1、SR2、NR3R4、C(=NH)NR3R4、NHC( = NH)NR3R4、CH=O、C(=O)OR5、CH(NR3R4)(C(=O) OR5)、C(=O)NR3R4、金属配位基、またはホスフェート基であり; G2はハロゲン、OH、SH、SCH3、またはNR3R4であり; G3はC(=O)、C(=S)、C(O)−O、C(O)−NH、C(S)− O、C(S)−NHまたはS(O)2であり; 各々のd1は独立して0または1であり; 各々のd2は独立して0から6であり; 各々のd3は独立して1から6であり; R1はH、1から約6の炭素原子を有するアルキル、またはヒドロキシル保護 基であり; R2はH、1から約6の炭素原子を有するアルキル、またはチオール保護基で あり; R3およびR4は独立してH、1から約6の炭素原子を有するアルキル、または アミン保護基であり; R5はH、1から約6の炭素原子を有するアルキル、または酸保護基であり; および E1およびE2の一つは前記ホスホジエステルまたはホスホロチオエートオリゴ ヌクレオチドを含み、および前記E1およびE2の他方がH、ヒドロキシル保護基 またはコンジュゲート基である]。 22. Lが約2から約10の炭素を有するアルキルである請求項21に記載の 化合物。 23. YおよびTが一緒に窒素ヘテロ環に組み込まれている請求項21に記載 の化合物。 24. 前記ヘテロ環がピペリジンまたはピロリジンである請求項23に記載の 化合物。 25. E1がH、ヒドロキシル保護基、または活性化固体支持体である請求項 21に記載の化合物。 26. E2がトリチル、メトキシトリチル、ジメトキシトリチルまたはトリメ トキシトリチルである請求項21に記載の化合物。 27. E2がHまたはヒドロキシル保護基である請求項21に記載の化合物。 28. Z2がHである請求項21に記載の化合物。 29. Z1がプリンまたはピリミジンである請求項21に記載の化合物。 30. Z1がアデニン、グアニン、シトシン、ウリジンまたはチミンである請 求項29に記載の化合物。 31. Z1が1から約20の炭素原子を有するアルキルである請求項1に記載 の化合物。 32. Z1が6から約14の炭素原子を有するアリールまたは7から約15の 炭素原子を有するアラルキルである請求項21に記載の化合物。 33. Z1がフルオレニルメチル、フェニル、またはベンジルである請求項2 1に記載の化合物。 34. Z1がポリエチレングリコールまたはグルタミルである請求項21に記 載の化合物。 35. mが約2から約25である請求項21に記載の化合物。 36. XがOである請求項21に記載の化合物。 37. XがSである請求項21に記載の化合物。 記載の化合物。 40. 少なくとも一つの前記L基が他の前記L基と異なっている請求項21に 記載の化合物。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/200,638 | 1994-02-23 | ||
| US200,638 | 1994-02-23 | ||
| US08/200,638 US5637684A (en) | 1994-02-23 | 1994-02-23 | Phosphoramidate and phosphorothioamidate oligomeric compounds |
| PCT/US1995/002267 WO1995023160A1 (en) | 1994-02-23 | 1995-02-23 | Novel phosphoramidate and phophorothioamidate oligomeric compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH09509663A true JPH09509663A (ja) | 1997-09-30 |
| JP2972344B2 JP2972344B2 (ja) | 1999-11-08 |
Family
ID=22742548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7522463A Expired - Fee Related JP2972344B2 (ja) | 1994-02-23 | 1995-02-23 | 新規ホスホルアミデートおよびホスホロチオアミデートオリゴマー化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5637684A (ja) |
| EP (1) | EP0751948B1 (ja) |
| JP (1) | JP2972344B2 (ja) |
| AT (1) | ATE224908T1 (ja) |
| AU (1) | AU677150B2 (ja) |
| CA (1) | CA2184005C (ja) |
| DE (1) | DE69528362D1 (ja) |
| WO (1) | WO1995023160A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013520206A (ja) * | 2010-02-24 | 2013-06-06 | ザ ブロード インスティテュート, インコーポレイテッド | 感染性疾患の病原体およびそれらの薬剤感受性を診断する方法 |
| WO2018230624A1 (ja) * | 2017-06-16 | 2018-12-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 修飾核酸モノマー化合物及びオリゴ核酸類縁体 |
Families Citing this family (349)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962219A (en) * | 1990-06-11 | 1999-10-05 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chemi-selex |
| US5919965A (en) * | 1995-01-18 | 1999-07-06 | Genzyme Corporation | Non-nucleotide phosphorus ester oligomers |
| US5969135A (en) * | 1995-11-02 | 1999-10-19 | Icn Pharmaceuticals, Inc. | Oligonucleotide analogs with an amino acid or a modified amino alcohol residue |
| EP0880532A4 (en) * | 1996-02-01 | 1999-06-09 | Pharmagenics Inc | NON-NUCLEOTIDE PHOSPHOROUS ESTER OLIGOMERS |
| AU4585197A (en) | 1996-09-20 | 1998-04-14 | President And Fellows Of Harvard College | Combinatorial approach for generating novel coordination complexes |
| US5908845A (en) * | 1996-10-30 | 1999-06-01 | Segev; David | Polyether nucleic acids |
| AU4964897A (en) * | 1996-11-13 | 1998-06-03 | Chugai Seiyaku Kabushiki Kaisha | H-phosphonate oligonucleotide derivative and process for producing the derivative |
| US5789333A (en) * | 1997-03-05 | 1998-08-04 | Iowa State University Research Foundation, Inc. | Catalyst system comprising a first catalyst system tethered to a supported catalyst |
| US7252950B1 (en) | 1997-09-04 | 2007-08-07 | The Regents Of The University Of California | Assays for detecting modulators of cytoskeletal function |
| US7115884B1 (en) | 1997-10-06 | 2006-10-03 | Trustees Of Tufts College | Self-encoding fiber optic sensor |
| WO1999034806A1 (en) | 1998-01-08 | 1999-07-15 | The Regents Of The University Of California | KINESIN MOTOR MODULATORS DERIVED FROM THE MARINE SPONGE $i(ADOCIA) |
| US6764830B1 (en) | 1998-01-23 | 2004-07-20 | The Regents Of The University Of California | Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins |
| DE69940430D1 (de) | 1998-06-24 | 2009-04-02 | Illumina Inc | Dekodierung von matrixartig-angeordneten Sensoren durch Mikropartikel |
| US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
| US6492111B1 (en) | 1998-11-25 | 2002-12-10 | Isis Pharmaceuticals, Inc. | In situ binary synthesis of biologically effective molecules |
| US6429027B1 (en) | 1998-12-28 | 2002-08-06 | Illumina, Inc. | Composite arrays utilizing microspheres |
| CA2364305A1 (en) | 1999-03-31 | 2000-10-05 | The University Of North Carolina At Chapel Hill | Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same |
| US20060275782A1 (en) | 1999-04-20 | 2006-12-07 | Illumina, Inc. | Detection of nucleic acid reactions on bead arrays |
| DK1923471T3 (da) | 1999-04-20 | 2013-04-02 | Illumina Inc | Detektion af nukleinsyrereaktioner på bead-arrays |
| CA2374390A1 (en) | 1999-05-20 | 2000-12-14 | Illumina, Inc. | Combinatorial decoding of random nucleic acid arrays |
| DK1210357T3 (da) | 1999-09-10 | 2008-07-21 | Geron Corp | Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf |
| AU3838901A (en) | 2000-02-16 | 2001-08-27 | Illumina Inc | Parallel genotyping of multiple patient samples |
| EP2264072A1 (en) | 2000-04-13 | 2010-12-22 | The Rockefeller University | Enhancement of antibody-mediated cytotoxicity. |
| DE10041539A1 (de) * | 2000-08-24 | 2002-03-07 | Febit Ferrarius Biotech Gmbh | Neue Amiditderivate zur Synthese von Polymeren auf Oberflächen |
| ES2291362T3 (es) * | 2000-09-14 | 2008-03-01 | Mount Sinai School Of Medicine | Procedimientos de cribado para identificar proteinas g y otros compuestos que modulan la actividad de la fosfodiesterasa (pde). |
| US20030044803A1 (en) * | 2000-09-22 | 2003-03-06 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of JAK1 |
| US20020115058A1 (en) * | 2000-09-22 | 2002-08-22 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1 |
| US20030077590A1 (en) * | 2000-09-22 | 2003-04-24 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin |
| US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
| EP1736760A3 (en) | 2000-12-11 | 2008-06-18 | President And Fellows Of Harvard College | Nanosensors |
| US20030232334A1 (en) * | 2000-12-22 | 2003-12-18 | Morris David W. | Novel compositions and methods for cancer |
| US7820447B2 (en) * | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
| US20030087252A1 (en) * | 2000-12-22 | 2003-05-08 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of PRDM11 |
| US7700274B2 (en) * | 2000-12-22 | 2010-04-20 | Sagres Discovery, Inc. | Compositions and methods in cancer associated with altered expression of KCNJ9 |
| US20030099963A1 (en) * | 2000-12-22 | 2003-05-29 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of TBX21 |
| US7892730B2 (en) * | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
| US7645441B2 (en) | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
| US20030165878A1 (en) * | 2000-12-22 | 2003-09-04 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of MCM3AP |
| US20030036854A1 (en) * | 2001-02-06 | 2003-02-20 | The Penn State Research Foundation | Apparatus and method for designing proteins and protein libraries |
| EP1572871A4 (en) * | 2001-04-20 | 2007-11-14 | Sinai School Medicine | T1R3, A NEW TASTE RECEPTOR |
| US7803982B2 (en) | 2001-04-20 | 2010-09-28 | The Mount Sinai School Of Medicine Of New York University | T1R3 transgenic animals, cells and related methods |
| US6534646B2 (en) * | 2001-06-04 | 2003-03-18 | Barrskogen, Inc. | Oligonucleotide labeling reagents |
| AU2002365421A1 (en) | 2001-07-10 | 2003-09-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detecting the activation state of the multiple proteins in single cells |
| US7393656B2 (en) * | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
| US7381535B2 (en) | 2002-07-10 | 2008-06-03 | The Board Of Trustees Of The Leland Stanford Junior | Methods and compositions for detecting receptor-ligand interactions in single cells |
| EP1481076A4 (en) | 2001-07-12 | 2005-05-11 | Illumina Inc | MULTIPLEX NUCLEIC REACTIONS |
| CA2563510A1 (en) * | 2001-07-13 | 2005-11-17 | Nanosphere, Inc. | Method for preparing substrates having immobilized molecules and substrates |
| US7687437B2 (en) * | 2001-07-13 | 2010-03-30 | Nanosphere, Inc. | Method for immobilizing molecules onto surfaces |
| US7297553B2 (en) * | 2002-05-28 | 2007-11-20 | Nanosphere, Inc. | Method for attachment of silylated molecules to glass surfaces |
| EP1427821B1 (en) * | 2001-08-20 | 2007-06-20 | Regenesis Bioremediation Products | Biosensor for small molecule analytes |
| US20070098728A1 (en) * | 2001-09-24 | 2007-05-03 | Pedersen Finn S | Novel compositions and methods in cancer |
| CA2495529C (en) | 2001-10-01 | 2009-05-19 | Mount Sinai School Of Medicine Of New York University | Noonan syndrome gene |
| US20040166490A1 (en) * | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
| US20040126762A1 (en) * | 2002-12-17 | 2004-07-01 | Morris David W. | Novel compositions and methods in cancer |
| WO2003038035A2 (en) * | 2001-10-26 | 2003-05-08 | Genencor International, Inc. | T. reesei phytase enzymes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
| AU2002356855A1 (en) * | 2001-10-26 | 2003-05-12 | Genencor International, Inc. | Phytase enzymes, nucleic acid sequences encoding phytase enzymes and vectors and host cells incorporating same |
| US20040197778A1 (en) * | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
| US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
| US20040180344A1 (en) * | 2003-03-14 | 2004-09-16 | Morris David W. | Novel therapeutic targets in cancer |
| JP2005526497A (ja) * | 2002-02-04 | 2005-09-08 | ビオミラ,インコーポレーテッド | 免疫刺激性、共有結合性脂質化オリゴヌクレオチド |
| AU2003215240A1 (en) * | 2002-02-14 | 2003-09-04 | Illumina, Inc. | Automated information processing in randomly ordered arrays |
| EP2110434A1 (en) | 2002-02-25 | 2009-10-21 | Genentech, Inc. | Type-1 cytokine receptor GLM-R |
| EP1501855A4 (en) * | 2002-03-21 | 2006-02-22 | Sagres Discovery Inc | NEW COMPOSITIONS AND METHODS FOR CANCER |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| JP2005523701A (ja) | 2002-04-26 | 2005-08-11 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | 二本鎖核酸−特異的色素を使用する二次構造の融解分析による一本鎖核酸の特徴付け |
| US20030220844A1 (en) * | 2002-05-24 | 2003-11-27 | Marnellos Georgios E. | Method and system for purchasing genetic data |
| AU2003301353A1 (en) * | 2002-10-18 | 2004-05-04 | Cylene Pharmaceuticals | Processes for identifying quadruplex-targeted antiviral molecules |
| AU2013202894B2 (en) * | 2002-10-25 | 2014-09-25 | Honeywell International, Inc. | Compositions containing flourine substituted olefins |
| EP2112229A3 (en) | 2002-11-25 | 2009-12-02 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| US9169516B2 (en) | 2003-01-24 | 2015-10-27 | University Of Utah Research Foundation | Methods of predicting mortality risk by determining telomere length |
| EP2058408A3 (en) | 2003-02-14 | 2009-09-09 | Sagres Discovery, Inc. | Therapeutic GPCR targets in cancer |
| US7767387B2 (en) * | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
| US20070218071A1 (en) * | 2003-09-15 | 2007-09-20 | Morris David W | Novel therapeutic targets in cancer |
| US6943768B2 (en) | 2003-02-21 | 2005-09-13 | Xtellus Inc. | Thermal control system for liquid crystal cell |
| US8324365B2 (en) * | 2003-04-03 | 2012-12-04 | Korea Advanced Institute Of Science And Technology | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
| US20050043510A1 (en) * | 2003-04-10 | 2005-02-24 | Moeckli Randolph A. | Affinity purification system using troponin molecules as affinity ligands |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US20060286545A1 (en) * | 2003-05-23 | 2006-12-21 | Mount Sinai School Of Medicine Of New York University | Viral vectors with improved properties |
| US20040259100A1 (en) | 2003-06-20 | 2004-12-23 | Illumina, Inc. | Methods and compositions for whole genome amplification and genotyping |
| US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
| US7947817B2 (en) * | 2003-06-30 | 2011-05-24 | Roche Molecular Systems, Inc. | Synthesis and compositions of 2'-terminator nucleotides |
| US20050095627A1 (en) * | 2003-09-03 | 2005-05-05 | The Salk Institute For Biological Studies | Multiple antigen detection assays and reagents |
| US20070281896A1 (en) * | 2003-09-30 | 2007-12-06 | Morris David W | Novel compositions and methods in cancer |
| US7259258B2 (en) | 2003-12-17 | 2007-08-21 | Illumina, Inc. | Methods of attaching biological compounds to solid supports using triazine |
| US20050136414A1 (en) * | 2003-12-23 | 2005-06-23 | Kevin Gunderson | Methods and compositions for making locus-specific arrays |
| US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
| US20050266432A1 (en) * | 2004-02-26 | 2005-12-01 | Illumina, Inc. | Haplotype markers for diagnosing susceptibility to immunological conditions |
| EP1804059A2 (en) | 2004-05-21 | 2007-07-04 | Atonomics A/S | Surface acoustic wave sensor comprising a hydrogel |
| US7745125B2 (en) * | 2004-06-28 | 2010-06-29 | Roche Molecular Systems, Inc. | 2′-terminator related pyrophosphorolysis activated polymerization |
| US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
| US20060105348A1 (en) * | 2004-11-15 | 2006-05-18 | Lee Jun E | Compositions and methods for the detection and discrimination of nucleic acids |
| US20060275792A1 (en) * | 2004-11-15 | 2006-12-07 | Lee Jun E | Enhancement of nucleic acid amplification using double-stranded DNA binding proteins |
| US7842794B2 (en) | 2004-12-17 | 2010-11-30 | Roche Molecular Systems, Inc. | Reagents and methods for detecting Neisseria gonorrhoeae |
| DE102004063599B4 (de) | 2004-12-30 | 2007-07-12 | Bayer Innovation Gmbh | Verkürzte Wundheilungsprozesse mittels neuartiger Faservliese |
| CN101107021A (zh) * | 2004-12-30 | 2008-01-16 | 金文申有限公司 | 包含信号提供试剂、植入物材料和药物的组合 |
| EA011516B1 (ru) * | 2005-01-13 | 2009-04-28 | Синвеншен Аг | Композиционный материал и способ его изготовления |
| CA2591944A1 (en) * | 2005-01-24 | 2006-07-27 | Cinvention Ag | Metal containing composite materials |
| AU2006224582A1 (en) * | 2005-03-18 | 2006-09-21 | Cinvention Ag | Process for the preparation of porous sintered metal materials |
| US20090264299A1 (en) * | 2006-02-24 | 2009-10-22 | Complete Genomics, Inc. | High throughput genome sequencing on DNA arrays |
| EP3257949A1 (en) | 2005-06-15 | 2017-12-20 | Complete Genomics Inc. | Nucleic acid analysis by random mixtures of non-overlapping fragments |
| US8067208B2 (en) | 2005-06-30 | 2011-11-29 | Roche Molecular Systems, Inc. | Probes and methods for hepatitis C virus typing using multidimensional probe analysis |
| EP1902087A1 (en) * | 2005-07-01 | 2008-03-26 | Cinvention Ag | Process for the production of porous reticulated composite materials |
| WO2007003516A2 (en) * | 2005-07-01 | 2007-01-11 | Cinvention Ag | Medical devices comprising a reticulated composite material |
| CA2624906A1 (en) * | 2005-10-18 | 2007-04-26 | Cinvention Ag | Thermoset particles and methods for production thereof |
| EP3061834B1 (en) | 2005-10-21 | 2020-01-08 | The Regents of the University of California | Shp-2 gene mutations in melanoma |
| WO2007056113A2 (en) * | 2005-11-02 | 2007-05-18 | Cylene Pharmaceuticals, Inc. | Methods for targeting quadruplex sequences |
| EP1991274A4 (en) | 2006-01-20 | 2009-06-10 | Women S And Children S Health | METHOD OF TREATMENT, PROPHYLAXIS AND DIAGNOSIS OF BONE PATHOLOGIES |
| EP2495337A1 (en) | 2006-02-24 | 2012-09-05 | Callida Genomics, Inc. | High throughput genome sequencing on DNA arrays |
| US7914988B1 (en) | 2006-03-31 | 2011-03-29 | Illumina, Inc. | Gene expression profiles to predict relapse of prostate cancer |
| EP2677039B8 (en) | 2006-05-10 | 2022-10-05 | DxTerity Diagnostics Incorporated | Detection of nucleic acid targets using chemically reactive oligonucleotide probes |
| US20080063637A1 (en) * | 2006-05-19 | 2008-03-13 | The Trustees Of Tufts College | Regulation of oncogenesis by Akt-specific isoforms |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| US8637436B2 (en) | 2006-08-24 | 2014-01-28 | California Institute Of Technology | Integrated semiconductor bioarray |
| WO2007143669A2 (en) | 2006-06-05 | 2007-12-13 | California Institute Of Technology | Real time micro arrays |
| US11001881B2 (en) | 2006-08-24 | 2021-05-11 | California Institute Of Technology | Methods for detecting analytes |
| US11525156B2 (en) | 2006-07-28 | 2022-12-13 | California Institute Of Technology | Multiplex Q-PCR arrays |
| US8048626B2 (en) | 2006-07-28 | 2011-11-01 | California Institute Of Technology | Multiplex Q-PCR arrays |
| US11560588B2 (en) | 2006-08-24 | 2023-01-24 | California Institute Of Technology | Multiplex Q-PCR arrays |
| WO2008033518A2 (en) | 2006-09-13 | 2008-03-20 | The Trustees Of Columbia University In The City Of New York | Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass |
| EP2066814A4 (en) | 2006-09-14 | 2010-12-29 | Univ California | MOLECULAR NANOPLASMONIC LINEAL FOR NUCLEASE ACTIVITY AND DNA FOOTPRINT |
| EP1914303A1 (en) * | 2006-10-09 | 2008-04-23 | Qiagen GmbH | Thermus eggertssonii DNA polymerases |
| WO2008070352A2 (en) | 2006-10-27 | 2008-06-12 | Complete Genomics, Inc. | Efficient arrays of amplified polynucleotides |
| US20090111706A1 (en) | 2006-11-09 | 2009-04-30 | Complete Genomics, Inc. | Selection of dna adaptor orientation by amplification |
| US20080242560A1 (en) * | 2006-11-21 | 2008-10-02 | Gunderson Kevin L | Methods for generating amplified nucleic acid arrays |
| US9938641B2 (en) * | 2006-12-18 | 2018-04-10 | Fluidigm Corporation | Selection of aptamers based on geometry |
| US7858772B2 (en) * | 2006-12-22 | 2010-12-28 | Roche Molecular Systems, Inc. | Compounds and methods for synthesis and purification of oligonucleotides |
| CN101646402A (zh) * | 2007-01-19 | 2010-02-10 | 金文申有限公司 | 用粉末模塑法制成的多孔、不可降解植入物 |
| US20080206862A1 (en) * | 2007-02-28 | 2008-08-28 | Cinvention Ag | High surface cultivation system bag |
| US20080206734A1 (en) * | 2007-02-28 | 2008-08-28 | Cinvention Ag | High surface cultivation system with filler |
| CA2677699A1 (en) * | 2007-02-28 | 2008-09-04 | Cinvention Ag | High surface cultivation system |
| CA2677721A1 (en) * | 2007-02-28 | 2008-09-04 | Cinvention Ag | High surface cultivation system with surface increasing substrate |
| US20090136932A1 (en) * | 2007-03-16 | 2009-05-28 | Craighead Harold G | Fibers with isolated biomolecules and uses thereof |
| WO2008141799A1 (en) * | 2007-05-24 | 2008-11-27 | Roche Diagnostics Gmbh | Oligophosphoramidates |
| US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
| WO2009025847A2 (en) | 2007-08-21 | 2009-02-26 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| EP2192922A4 (en) | 2007-09-17 | 2010-09-29 | Univ California | INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES |
| WO2009061941A2 (en) | 2007-11-06 | 2009-05-14 | Osmetech Molecular Diagnostics | Baseless nucleotide analogues and uses thereof |
| DK2610351T3 (en) | 2007-12-05 | 2015-09-28 | Complete Genomics Inc | Base efficient provision of sequencing reactions |
| WO2009074325A1 (en) | 2007-12-13 | 2009-06-18 | Philip Morris Products S.A. | Transgenic plants modified for reduced cadmium transport, derivative products, and related methods |
| EP3699291B1 (en) | 2008-01-17 | 2024-08-07 | Sequenom, Inc. | Single molecule nucleic acid sequence analysis processes and compositions |
| US8709726B2 (en) * | 2008-03-11 | 2014-04-29 | Sequenom, Inc. | Nucleic acid-based tests for prenatal gender determination |
| US10150990B2 (en) | 2008-04-21 | 2018-12-11 | Roche Molecular Systems, Inc. | Ribonucleotide tag nucleic acid detection |
| AU2009248971B2 (en) | 2008-05-21 | 2015-04-30 | Kinemed, Inc. | Compositions and methods of treatment using modulators of motoneuron diseases |
| US8227202B2 (en) | 2008-07-10 | 2012-07-24 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| US8383585B2 (en) | 2008-07-17 | 2013-02-26 | Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh | Biomarkers for cardiodiabetes |
| WO2010009438A1 (en) | 2008-07-17 | 2010-01-21 | Andreas Pfuetzner | Biomarkers for insulin resistance and beta-cell dysfunction |
| ES2574137T3 (es) | 2008-09-03 | 2016-06-15 | Quantumdx Group Limited | Estrategias y métodos de detección de ácidos nucleicos mediante biosensores |
| US8871921B2 (en) | 2008-09-03 | 2014-10-28 | Quantumdx Group Ltd. | Design, synthesis and use of synthetic nucleotides comprising charge mass tags |
| US8476013B2 (en) * | 2008-09-16 | 2013-07-02 | Sequenom, Inc. | Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
| US8962247B2 (en) | 2008-09-16 | 2015-02-24 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses |
| EP2342334A4 (en) | 2008-09-29 | 2012-03-14 | Univ Pennsylvania | VACCINES DIRECTED TO TUMOR VESSEL MARKERS |
| DE102008043277A1 (de) * | 2008-10-29 | 2010-05-06 | Biotronik Vi Patent Ag | Implantat aus einer biokorrodierbaren Eisen- oder Magnesiumlegierung |
| US8309306B2 (en) * | 2008-11-12 | 2012-11-13 | Nodality, Inc. | Detection composition |
| WO2010060599A1 (en) * | 2008-11-27 | 2010-06-03 | Roche Diagnostics Gmbh | Directed synthesis of oligophosphoramidate stereoisomers |
| US20100256196A1 (en) | 2008-12-04 | 2010-10-07 | Ikfe | Biomarkers for Atherosclerosis |
| WO2010067207A1 (en) | 2008-12-11 | 2010-06-17 | Ikfe Gmbh | Biomarkers for insulin sensitizer drug response |
| EP2379747B1 (en) | 2008-12-22 | 2013-07-03 | University of Utah Research Foundation | Monochrome multiplex quantitative pcr |
| US20100209350A1 (en) | 2008-12-30 | 2010-08-19 | Andreas Pfuetzner | Biomarkers for Adipose Tissue Activity |
| WO2010079428A2 (en) | 2009-01-07 | 2010-07-15 | Ikfe Gmbh | Biomarkers for appetite regulation |
| US8206929B2 (en) | 2009-01-07 | 2012-06-26 | Roche Molecular Systems, Inc. | Nucleic acid amplification with allele-specific suppression of sequence variants |
| EP2391714B2 (en) | 2009-01-30 | 2019-07-24 | Whitehead Institute for Biomedical Research | Methods for ligation and uses thereof |
| US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
| AU2010232972B2 (en) * | 2009-04-01 | 2016-10-27 | Dxterity Diagnostics Incorporated | Chemical ligation dependent probe amplification (CLPA) |
| US20100297127A1 (en) | 2009-04-08 | 2010-11-25 | Ghilardi Nico P | Use of il-27 antagonists to treat lupus |
| US8871494B2 (en) | 2009-04-24 | 2014-10-28 | Wisconsin Alumni Research Foundation | Over-production of secondary metabolites by over-expression of the VEA gene |
| US20100279882A1 (en) * | 2009-05-01 | 2010-11-04 | Mostafa Ronaghi | Sequencing methods |
| CN102459592B (zh) | 2009-06-15 | 2017-04-05 | 考利达基因组股份有限公司 | 用于长片段阅读测序的方法和组合物 |
| US8614081B2 (en) | 2009-07-23 | 2013-12-24 | Codexis, Inc. | Nitrilase biocatalysts |
| US9523701B2 (en) | 2009-07-29 | 2016-12-20 | Dynex Technologies, Inc. | Sample plate systems and methods |
| GB0913258D0 (en) | 2009-07-29 | 2009-09-02 | Dynex Technologies Inc | Reagent dispenser |
| US9250234B2 (en) | 2011-01-19 | 2016-02-02 | Ohmx Corporation | Enzyme triggered redox altering chemical elimination (E-TRACE) immunoassay |
| US8530170B2 (en) | 2009-08-07 | 2013-09-10 | Ohmx Corporation | Enzyme triggered redox altering chemical elimination (E-trace) immunoassay |
| US8409802B2 (en) | 2009-08-14 | 2013-04-02 | Roche Molecular Systems, Inc. | Format of probes to detect nucleic acid differences |
| US9459246B2 (en) | 2009-09-08 | 2016-10-04 | Nodality, Inc. | Induced intercellular communication |
| US10174368B2 (en) | 2009-09-10 | 2019-01-08 | Centrillion Technology Holdings Corporation | Methods and systems for sequencing long nucleic acids |
| CN102858995B (zh) | 2009-09-10 | 2016-10-26 | 森特瑞隆技术控股公司 | 靶向测序方法 |
| WO2011038228A1 (en) | 2009-09-24 | 2011-03-31 | President And Fellows Of Harvard College | Bent nanowires and related probing of species |
| US8394948B2 (en) * | 2009-09-30 | 2013-03-12 | Glen Research Corporation | Reagents utilizing a serinol scaffold for labeling synthetic oligonucleotides |
| US8927215B2 (en) | 2009-10-30 | 2015-01-06 | The Regents Of The University Of California | GNA11 mutations in melanoma |
| US8614071B2 (en) | 2009-12-11 | 2013-12-24 | Roche Molecular Systems, Inc. | Preferential amplification of mRNA over DNA using chemically modified primers |
| US9926593B2 (en) | 2009-12-22 | 2018-03-27 | Sequenom, Inc. | Processes and kits for identifying aneuploidy |
| EP2525808A2 (en) | 2010-01-19 | 2012-11-28 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
| EP2525905B1 (en) | 2010-01-19 | 2020-11-04 | Illumina, Inc. | Methods and compositions for processing chemical reactions |
| WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
| US10232374B2 (en) | 2010-05-05 | 2019-03-19 | Miroculus Inc. | Method of processing dried samples using digital microfluidic device |
| ES2705236T3 (es) | 2010-05-12 | 2019-03-22 | Univ Columbia | Procedimientos para producir células enteroendocrinas que producen y secretan insulina |
| US9228240B2 (en) | 2010-06-03 | 2016-01-05 | California Institute Of Technology | Methods for detecting and quantifying viable bacterial endo-spores |
| EP2603607B1 (en) | 2010-08-11 | 2016-04-06 | Celula, Inc. | Genotyping dna |
| JP5917519B2 (ja) | 2010-09-10 | 2016-05-18 | バイオ−ラッド ラボラトリーズ インコーポレーティッド | クロマチン分析のためのdnaのサイズ選択 |
| US8483969B2 (en) | 2010-09-17 | 2013-07-09 | Illuminia, Inc. | Variation analysis for multiple templates on a solid support |
| EP2633069B1 (en) | 2010-10-26 | 2015-07-01 | Illumina, Inc. | Sequencing methods |
| CA2821299C (en) | 2010-11-05 | 2019-02-12 | Frank J. Steemers | Linking sequence reads using paired code tags |
| CA2821411C (en) | 2010-12-13 | 2020-02-25 | Quiapeg Pharmaceuticals Ab | Functionalized polymers |
| EP3733870A3 (en) | 2011-01-14 | 2021-01-27 | Life Technologies Corporation | Methods for identification and quantification of mirnas |
| ES2762866T3 (es) | 2011-01-28 | 2020-05-26 | Illumina Inc | Reemplazo de nucleótidos por bibliotecas doblemente etiquetadas y direccionales |
| EP2670864B1 (en) | 2011-01-31 | 2017-03-08 | Illumina, Inc. | Methods for reducing nucleic acid damage |
| CN103562407A (zh) | 2011-02-09 | 2014-02-05 | 伯乐生命医学产品有限公司 | 核酸的分析 |
| US20120208193A1 (en) | 2011-02-15 | 2012-08-16 | Bio-Rad Laboratories, Inc. | Detecting methylation in a subpopulation of genomic dna |
| US20120252682A1 (en) | 2011-04-01 | 2012-10-04 | Maples Corporate Services Limited | Methods and systems for sequencing nucleic acids |
| EP2702175B1 (en) | 2011-04-25 | 2018-08-08 | Bio-Rad Laboratories, Inc. | Methods and compositions for nucleic acid analysis |
| CA2834218C (en) | 2011-04-29 | 2021-02-16 | Sequenom, Inc. | Quantification of a minority nucleic acid species using inhibitory oligonucleotides |
| CN105132284B (zh) | 2011-05-13 | 2018-04-03 | 加利福尼亚大学董事会 | 用于选择性转染细胞的光热衬底 |
| EP2710145B1 (en) | 2011-05-17 | 2015-12-09 | Dxterity Diagnostics Incorporated | Methods and compositions for detecting target nucleic acids |
| CN103732761A (zh) | 2011-08-03 | 2014-04-16 | 伯乐实验室公司 | 使用透化处理的细胞过滤小核酸 |
| CN103797132A (zh) | 2011-09-23 | 2014-05-14 | 霍夫曼-拉罗奇有限公司 | G形夹用于改进的等位基因特异性pcr的用途 |
| JP6420148B2 (ja) | 2011-10-14 | 2018-11-07 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 矩形波サーマルサイクリング |
| CA2851632A1 (en) | 2011-10-17 | 2013-04-25 | Ohmx Corporation | Single, direct detection of hemoglobin a1c percentage using enzyme triggered redox altering chemical elimination (e-trace) immunoassay |
| SG11201401628WA (en) | 2011-10-19 | 2014-05-29 | Nugen Technologies Inc | Compositions and methods for directional nucleic acid amplification and sequencing |
| ES2791830T3 (es) | 2011-10-28 | 2020-11-06 | Univ California | Mutaciones de FLT3 asociadas a resistencia a fármacos en pacientes con aml que tienen mutaciones activadoras en FLT3 |
| US10837879B2 (en) | 2011-11-02 | 2020-11-17 | Complete Genomics, Inc. | Treatment for stabilizing nucleic acid arrays |
| US9340567B2 (en) | 2011-11-04 | 2016-05-17 | Ohmx Corporation | Chemistry used in biosensors |
| JP2015502365A (ja) | 2011-12-12 | 2015-01-22 | オンコイミューニン,インコーポレイティド | オリゴヌクレオチドのイン−ビボ送達 |
| US9745631B2 (en) | 2011-12-20 | 2017-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for diagnosing and treating oncogenic kras-associated cancer |
| US9115394B2 (en) | 2011-12-22 | 2015-08-25 | Roche Molecular Systems, Inc. | Methods and reagents for reducing non-specific amplification |
| US20130217071A1 (en) | 2011-12-30 | 2013-08-22 | Luz Montesclaros | Methods and compositions for performing nucleic acid amplification reactions |
| CA2860739A1 (en) | 2012-01-09 | 2013-07-18 | Ohmx Corporation | Enzyme cascade methods for e-trace assay signal amplification |
| SG10201504490QA (en) | 2012-01-26 | 2015-07-30 | Nugen Technologies Inc | Compositions And Methods For Targeted Nucleic Acid Sequence Enrichment And High Efficiency Library Generation |
| US9862994B2 (en) | 2012-02-09 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Selective nucleic acid amplification from nucleic acid pools |
| EP2820129A1 (en) | 2012-03-02 | 2015-01-07 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| KR20150016336A (ko) | 2012-05-21 | 2015-02-11 | 더 스크립스 리서치 인스티튜트 | 리보솜 폴리뉴클레오티드 및 관련 발현 시스템 |
| US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
| WO2013177426A2 (en) | 2012-05-24 | 2013-11-28 | Dana-Farber Cancer Institute, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer |
| AU2013276219B2 (en) | 2012-06-12 | 2018-03-08 | Quiapeg Pharmaceuticals Ab | Conjugates of biologically active molecules to functionalized polymers |
| US9957549B2 (en) | 2012-06-18 | 2018-05-01 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
| US20150011396A1 (en) | 2012-07-09 | 2015-01-08 | Benjamin G. Schroeder | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
| WO2014011928A1 (en) | 2012-07-13 | 2014-01-16 | Sequenom, Inc. | Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses |
| US20150285802A1 (en) | 2012-07-18 | 2015-10-08 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
| EP4071253A1 (en) | 2012-07-26 | 2022-10-12 | Illumina, Inc. | Compositions and methods for the amplification of nucleic acids |
| US20140322706A1 (en) | 2012-10-24 | 2014-10-30 | Jon Faiz Kayyem | Integrated multipelx target analysis |
| EP2912432B1 (en) | 2012-10-24 | 2018-07-04 | Genmark Diagnostics Inc. | Integrated multiplex target analysis |
| DK3553175T3 (da) | 2013-03-13 | 2021-08-23 | Illumina Inc | Fremgangsmåde til fremstilling af et nukleinsyresekvenseringsbibliotek |
| EP2971100A1 (en) | 2013-03-13 | 2016-01-20 | Sequenom, Inc. | Primers for dna methylation analysis |
| CN105228748B (zh) | 2013-03-15 | 2017-10-10 | 金马克诊断股份有限公司 | 用于操纵可变形流体容器的系统、方法和设备 |
| CN110186835B (zh) | 2013-03-15 | 2022-05-31 | Gpb科学有限公司 | 颗粒的片上微流体处理 |
| US20140274785A1 (en) | 2013-03-15 | 2014-09-18 | Marc Hellerstein | Biomarkers |
| WO2016019393A1 (en) | 2014-08-01 | 2016-02-04 | Gpb Scientific, Llc | Methods and systems for processing particles |
| CN105247042B (zh) | 2013-03-15 | 2021-06-11 | 普林斯顿大学理事会 | 用于高通量纯化的方法和设备 |
| WO2014152497A2 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
| US9347095B2 (en) | 2013-03-15 | 2016-05-24 | Bio-Rad Laboratories, Inc. | Digital assays for mutation detection |
| US20140274738A1 (en) | 2013-03-15 | 2014-09-18 | Nugen Technologies, Inc. | Sequential sequencing |
| CA2912216A1 (en) | 2013-05-22 | 2014-11-27 | Telomere Diagnostics, Inc. | Measures of short telomere abundance |
| EP3024948B1 (en) | 2013-07-25 | 2020-01-15 | Bio-rad Laboratories, Inc. | Genetic assays for detecting viral recombination rate |
| WO2015023724A1 (en) | 2013-08-13 | 2015-02-19 | The Scripps Research Institute | Cysteine-reactive ligand discovery in proteomes |
| JP2016537965A (ja) | 2013-10-11 | 2016-12-08 | ジェネンテック, インコーポレイテッド | Nsp4阻害剤及び使用方法 |
| JP6640079B2 (ja) | 2013-10-16 | 2020-02-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 小容積の粒子を調製するためのデバイス及び方法 |
| US9498778B2 (en) | 2014-11-11 | 2016-11-22 | Genmark Diagnostics, Inc. | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system |
| USD881409S1 (en) | 2013-10-24 | 2020-04-14 | Genmark Diagnostics, Inc. | Biochip cartridge |
| JP2016538882A (ja) | 2013-10-30 | 2016-12-15 | グリーン ライフ バイオテック,エルエルシー | カンキツグリーニング病のための病因定量システム及び治療方法 |
| WO2015073711A1 (en) | 2013-11-13 | 2015-05-21 | Nugen Technologies, Inc. | Compositions and methods for identification of a duplicate sequencing read |
| US9689033B2 (en) | 2013-11-26 | 2017-06-27 | Illumina, Inc. | Compositions and methods for polynucleotide sequencing |
| GB2537077B (en) | 2013-12-05 | 2018-05-09 | Centrillion Tech Holdings Corp | Methods for sequencing nucleic acids |
| EP3077430A4 (en) | 2013-12-05 | 2017-08-16 | Centrillion Technology Holdings Corporation | Modified surfaces |
| CN111118121B (zh) | 2013-12-05 | 2024-07-19 | 生捷科技控股公司 | 图案化阵列的制备 |
| US9243289B2 (en) | 2013-12-23 | 2016-01-26 | Roche Molecular Systems, Inc. | Method for screening reagents used in PCR assays |
| AU2015206336B2 (en) | 2014-01-16 | 2020-01-23 | Illumina, Inc. | Gene expression panel for prognosis of prostate cancer recurrence |
| WO2015131107A1 (en) | 2014-02-28 | 2015-09-03 | Nugen Technologies, Inc. | Reduced representation bisulfite sequencing with diversity adaptors |
| EP3736344A1 (en) | 2014-03-13 | 2020-11-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10350264B2 (en) | 2014-03-27 | 2019-07-16 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin |
| EP3122375B1 (en) | 2014-03-28 | 2021-03-03 | University of Washington through its Center for Commercialization | Breast and ovarian cancer vaccines |
| US11060139B2 (en) | 2014-03-28 | 2021-07-13 | Centrillion Technology Holdings Corporation | Methods for sequencing nucleic acids |
| DK3126372T3 (en) | 2014-03-30 | 2019-04-23 | Cepheid | MODIFIED THYMIN-POLYNUCLEOTID OIGOMER AND SIMILAR PROCEDURES |
| EP3154696B1 (en) | 2014-06-10 | 2020-04-08 | DxTerity Diagnostics Incorporated | Devices and methods for collecting and stabilizing biological samples |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| US10913973B2 (en) | 2014-09-17 | 2021-02-09 | Board Of Regents, The University Texas System | Methods and devices related to toehold-based strand displacement with loop-mediated isothermal amplification |
| WO2016077364A2 (en) | 2014-11-11 | 2016-05-19 | Genmark Diagnostics, Inc. | Instrument and cartridge for performing assays in a closed sample preparation and reaction system |
| US9598722B2 (en) | 2014-11-11 | 2017-03-21 | Genmark Diagnostics, Inc. | Cartridge for performing assays in a closed sample preparation and reaction system |
| US10005080B2 (en) | 2014-11-11 | 2018-06-26 | Genmark Diagnostics, Inc. | Instrument and cartridge for performing assays in a closed sample preparation and reaction system employing electrowetting fluid manipulation |
| JP7175608B2 (ja) | 2014-11-19 | 2022-11-21 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 加齢に伴うフレイルのための治療としてのオステオカルシン |
| US9909169B2 (en) | 2014-12-17 | 2018-03-06 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression |
| WO2016108954A1 (en) | 2014-12-30 | 2016-07-07 | Telomere Diagnostics, Inc. | Multiplex quantitative pcr |
| SG11201706504RA (en) | 2015-02-10 | 2017-09-28 | Illumina Inc | Methods and compositions for analyzing cellular components |
| WO2016138175A1 (en) | 2015-02-24 | 2016-09-01 | The University Of British Columbia | Continuous flow microfluidic system |
| US9708647B2 (en) | 2015-03-23 | 2017-07-18 | Insilixa, Inc. | Multiplexed analysis of nucleic acid hybridization thermodynamics using integrated arrays |
| CA2980010C (en) | 2015-03-27 | 2023-10-03 | The Scripps Research Institute | Lipid probes and uses thereof |
| CN107872982B (zh) | 2015-03-31 | 2022-10-28 | 昂科赛克医疗公司 | 用于改进的基于组织感测的电穿孔的系统和方法 |
| CN104845967B (zh) | 2015-04-15 | 2020-12-11 | 苏州新海生物科技股份有限公司 | 寡聚核苷酸片段及使用其的选择性扩增目标核酸序列变异体的方法及应用 |
| US20180156807A1 (en) | 2015-04-29 | 2018-06-07 | New York University | Method for treating high-grade gliomas |
| WO2016197106A1 (en) | 2015-06-05 | 2016-12-08 | Miroculus Inc. | Evaporation management in digital microfluidic devices |
| WO2016197103A1 (en) | 2015-06-05 | 2016-12-08 | Miroculus Inc. | Air-matrix digital microfluidics apparatuses and methods for limiting evaporation and surface fouling |
| EP3103885B1 (en) | 2015-06-09 | 2019-01-30 | Centrillion Technology Holdings Corporation | Methods for sequencing nucleic acids |
| CA2988982A1 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| WO2017027783A1 (en) | 2015-08-13 | 2017-02-16 | Centrillion Technology Holdings Corporation | Methods for synchronising nucleic acid molecules |
| KR20180054639A (ko) | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| CN108351349B (zh) | 2015-09-10 | 2020-09-29 | 因斯利克萨公司 | 用于多路定量核酸扩增的方法和系统 |
| US9499861B1 (en) | 2015-09-10 | 2016-11-22 | Insilixa, Inc. | Methods and systems for multiplex quantitative nucleic acid amplification |
| EP4218833A1 (en) | 2015-10-01 | 2023-08-02 | Whitehead Institute for Biomedical Research | Labeling of antibodies |
| CN116003596A (zh) | 2015-10-29 | 2023-04-25 | 艾利妥 | 抗siglec-9抗体及其使用方法 |
| US10946106B2 (en) | 2015-11-30 | 2021-03-16 | The Regents Of The University Of California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
| CN108778477B (zh) | 2016-01-06 | 2022-02-25 | 不列颠哥伦比亚大学 | 分叉混合器及其使用和制造方法 |
| WO2017155858A1 (en) | 2016-03-07 | 2017-09-14 | Insilixa, Inc. | Nucleic acid sequence identification using solid-phase cyclic single base extension |
| WO2017181163A2 (en) | 2016-04-16 | 2017-10-19 | Oncocyte Corporation | Methods and compositions for detection and diagnosis of breast cancer |
| WO2017192743A1 (en) | 2016-05-04 | 2017-11-09 | Abilita Bio, Inc. | Methods and platform for preparing multispanning membrane proteins |
| ES2929367T3 (es) | 2016-05-18 | 2022-11-28 | Hoffmann La Roche | Amplificación por PCR ultrarrápida cuantitativa usando un dispositivo basado en electrohumectación |
| AU2017277631B2 (en) | 2016-06-09 | 2024-01-25 | The Regents Of The University Of California | Biomarker concentration and signal amplification for use in paper-based immunoassays and a single platform for extracting, concentrating, and amplifying DNA |
| CN109715781A (zh) | 2016-08-22 | 2019-05-03 | 米罗库鲁斯公司 | 用于数字微流控设备中的并行液滴控制的反馈系统 |
| US11300578B2 (en) | 2016-09-19 | 2022-04-12 | Roche Molecular Systems, Inc. | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system |
| EP3538551A4 (en) | 2016-11-10 | 2020-11-11 | Fortis Therapeutics, Inc. | CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF |
| CA3043277A1 (en) | 2016-11-11 | 2018-05-17 | The Regents Of The University Of California | Anti-cd46 antibodies and methods of use |
| US11147249B2 (en) | 2016-12-08 | 2021-10-19 | Alector Llc | Siglec transgenic mice and methods of use thereof |
| EP3563151A4 (en) | 2016-12-28 | 2020-08-19 | Miroculus Inc. | DIGITAL MICROFLUIDIC DEVICES AND METHODS |
| EP3570829A4 (en) | 2017-01-18 | 2021-03-10 | The Scripps Research Institute | PHOTOREACTIVE LIGANDS AND USES THEREOF |
| WO2018140329A1 (en) | 2017-01-24 | 2018-08-02 | Tsavachidou Dimitra | Methods for constructing copies of nucleic acid molecules |
| AU2018231832A1 (en) | 2017-03-10 | 2019-08-08 | Quiapeg Pharmaceuticals Ab | Releasable conjugates |
| US11623219B2 (en) | 2017-04-04 | 2023-04-11 | Miroculus Inc. | Digital microfluidics apparatuses and methods for manipulating and processing encapsulated droplets |
| US12492430B2 (en) | 2017-04-11 | 2025-12-09 | Tecan Genomics, Inc. | Library quantitation and qualification |
| US11299776B2 (en) | 2017-05-10 | 2022-04-12 | Board Of Regents, The University Of Texas System | Methods and devices related to amplifying nucleic acid at a variety of temperatures |
| US11359014B2 (en) | 2017-05-16 | 2022-06-14 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| CN110785663A (zh) | 2017-05-31 | 2020-02-11 | 加利福尼亚大学董事会 | 单步atps增强型lfa诊断设计 |
| US11413617B2 (en) | 2017-07-24 | 2022-08-16 | Miroculus Inc. | Digital microfluidics systems and methods with integrated plasma collection device |
| AU2018310985A1 (en) | 2017-08-03 | 2019-11-07 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| JP7341124B2 (ja) | 2017-09-01 | 2023-09-08 | ミロキュラス インコーポレイテッド | デジタルマイクロ流体デバイスおよびその使用方法 |
| US11099202B2 (en) | 2017-10-20 | 2021-08-24 | Tecan Genomics, Inc. | Reagent delivery system |
| US11691141B2 (en) | 2017-11-13 | 2023-07-04 | Roche Sequencing Solutions, Inc. | Devices for sample analysis using epitachophoresis |
| US11728007B2 (en) | 2017-11-30 | 2023-08-15 | Grail, Llc | Methods and systems for analyzing nucleic acid sequences using mappability analysis and de novo sequence assembly |
| US11470827B2 (en) | 2017-12-12 | 2022-10-18 | Alector Llc | Transgenic mice expressing human TREM proteins and methods of use thereof |
| US20210189460A1 (en) | 2018-04-25 | 2021-06-24 | Qiagen Sciences Llc | Sequential paired-end sequencing |
| CA3096855A1 (en) | 2018-05-23 | 2019-11-28 | Miroculus Inc. | Control of evaporation in digital microfluidics |
| KR20210030341A (ko) | 2018-06-08 | 2021-03-17 | 알렉터 엘엘씨 | 항-Siglec-7 항체 및 그의 사용 방법 |
| WO2020014704A1 (en) | 2018-07-13 | 2020-01-16 | University Of Hawaii | Point-of-care electroflotation of dispersed, low tolerance pathogens |
| KR20210049106A (ko) | 2018-07-27 | 2021-05-04 | 알렉터 엘엘씨 | 항-siglec-5 항체 및 이의 사용 방법 |
| SG11202101552SA (en) | 2018-08-31 | 2021-03-30 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| EP3849660A1 (en) | 2018-09-12 | 2021-07-21 | QuiaPEG Pharmaceuticals AB | Releasable glp-1 conjugates |
| AU2019342197B2 (en) | 2018-09-21 | 2025-10-16 | President And Fellows Of Harvard College | Methods and compositions for treating diabetes, and methods for enriching mRNA coding for secreted proteins |
| WO2020074742A1 (en) | 2018-10-12 | 2020-04-16 | F. Hoffmann-La Roche Ag | Detection methods for epitachophoresis workflow automation |
| NL2022043B1 (en) | 2018-11-21 | 2020-06-03 | Akershus Univ Hf | Tagmentation-Associated Multiplex PCR Enrichment Sequencing |
| CN112639126A (zh) | 2018-12-14 | 2021-04-09 | 伊卢米纳剑桥有限公司 | 降低测序期间用未标记的核苷酸的定相 |
| CN112654714B (zh) | 2018-12-17 | 2024-10-11 | 伊卢米纳剑桥有限公司 | 用于测序的引物寡核苷酸 |
| ES3032918T3 (en) | 2018-12-17 | 2025-07-28 | Illumina Cambridge Ltd | Method of polynucleotide sequencing |
| WO2020160520A1 (en) | 2019-01-31 | 2020-08-06 | Miroculus Inc. | Non fouling compositions and methods for manipulating and processing encapsulated droplets |
| CN119510370A (zh) | 2019-03-14 | 2025-02-25 | 因斯利克萨公司 | 基于时间门控的荧光检测的方法和系统 |
| WO2020210292A1 (en) | 2019-04-08 | 2020-10-15 | Miroculus Inc. | Multi-cartridge digital microfluidics apparatuses and methods of use |
| WO2020229437A1 (en) | 2019-05-14 | 2020-11-19 | F. Hoffmann-La Roche Ag | Devices and methods for sample analysis |
| US12577627B2 (en) | 2019-06-03 | 2026-03-17 | Arizona Board Of Regents On Behalf Of Arizone State University | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions |
| US11377655B2 (en) | 2019-07-16 | 2022-07-05 | Pacific Biosciences Of California, Inc. | Synthetic nucleic acids having non-natural structures |
| WO2021016614A1 (en) | 2019-07-25 | 2021-01-28 | Miroculus Inc. | Digital microfluidics devices and methods of use thereof |
| US11180520B2 (en) | 2019-09-10 | 2021-11-23 | Omniome, Inc. | Reversible modifications of nucleotides |
| US12059674B2 (en) | 2020-02-03 | 2024-08-13 | Tecan Genomics, Inc. | Reagent storage system |
| WO2021243271A2 (en) | 2020-05-29 | 2021-12-02 | Front Range Biosciences, Inc. | Methods and compositions for pathogen detection in plants |
| WO2022006019A1 (en) | 2020-06-29 | 2022-01-06 | Front Range Biosciences, Inc. | Characterization of cannabis cultivars based on terpene synthase gene profiles |
| US11484604B2 (en) | 2020-08-07 | 2022-11-01 | Fortis Therapeutics, Inc. | Immunoconjugates targeting CD46 and methods of use thereof |
| US12480157B2 (en) | 2021-09-30 | 2025-11-25 | Illumina, Inc. | Polynucleotide sequencing |
| EP4457364A1 (en) | 2021-12-29 | 2024-11-06 | Illumina, Inc. | Methods of nucleic acid sequencing using surface-bound primers |
| US11772093B2 (en) | 2022-01-12 | 2023-10-03 | Miroculus Inc. | Methods of mechanical microfluidic manipulation |
| US20240401129A1 (en) | 2023-05-31 | 2024-12-05 | Illumina, Inc. | Methods for double-stranded sequencing by synthesis |
| WO2025090427A1 (en) | 2023-10-23 | 2025-05-01 | University Of Rochester | Glial-targeted relief of hyperexcitability in neurodegenerative diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) * | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4547569A (en) * | 1982-11-24 | 1985-10-15 | The United States Of America As Represented By The Department Of Health And Human Services | Intercalating agents specifying nucleotides |
| US4959463A (en) * | 1985-10-15 | 1990-09-25 | Genentech, Inc. | Intermediates |
| US5218103A (en) * | 1988-05-26 | 1993-06-08 | University Patents, Inc. | Nucleoside thiophosphoramidites |
| US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5578718A (en) * | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| IE66205B1 (en) * | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
| WO1993004204A1 (en) * | 1991-08-23 | 1993-03-04 | Isis Pharmaceuticals, Inc. | Synthetic unrandomization of oligomer fragments |
| ATE239484T1 (de) * | 1991-10-24 | 2003-05-15 | Isis Pharmaceuticals Inc | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
| US5272250A (en) * | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
| WO1994004550A1 (en) * | 1992-08-21 | 1994-03-03 | Triplex Pharmaceutical Corporation | Cholesteryl-modified triple-helix forming oligonucleotides and uses thereof |
| US5362899A (en) * | 1993-09-09 | 1994-11-08 | Affymax Technologies, N.V. | Chiral synthesis of alpha-aminophosponic acids |
| US5587471A (en) * | 1994-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Method of making oligonucleotide libraries |
| US5519134A (en) * | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
-
1994
- 1994-02-23 US US08/200,638 patent/US5637684A/en not_active Expired - Lifetime
-
1995
- 1995-02-23 EP EP95912595A patent/EP0751948B1/en not_active Expired - Lifetime
- 1995-02-23 US US08/693,112 patent/US5717083A/en not_active Expired - Lifetime
- 1995-02-23 JP JP7522463A patent/JP2972344B2/ja not_active Expired - Fee Related
- 1995-02-23 WO PCT/US1995/002267 patent/WO1995023160A1/en not_active Ceased
- 1995-02-23 CA CA002184005A patent/CA2184005C/en not_active Expired - Fee Related
- 1995-02-23 AT AT95912595T patent/ATE224908T1/de not_active IP Right Cessation
- 1995-02-23 AU AU19691/95A patent/AU677150B2/en not_active Ceased
- 1995-02-23 DE DE69528362T patent/DE69528362D1/de not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013520206A (ja) * | 2010-02-24 | 2013-06-06 | ザ ブロード インスティテュート, インコーポレイテッド | 感染性疾患の病原体およびそれらの薬剤感受性を診断する方法 |
| US9885088B2 (en) | 2010-02-24 | 2018-02-06 | The Broad Institute, Inc. | Rapid phenotypic diagnosis of pathogens and drug resistance using transcriptional expression signatures |
| US10982291B2 (en) | 2010-02-24 | 2021-04-20 | The Broad Institute, Inc. | Methods of diagnosing infectious disease pathogens and their drug sensitivity |
| WO2018230624A1 (ja) * | 2017-06-16 | 2018-12-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 修飾核酸モノマー化合物及びオリゴ核酸類縁体 |
| JPWO2018230624A1 (ja) * | 2017-06-16 | 2020-06-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 修飾核酸モノマー化合物及びオリゴ核酸類縁体 |
| US11208429B2 (en) | 2017-06-16 | 2021-12-28 | Eisai R&D Management Co., Ltd. | Modified nucleic acid monomer compound and oligonucleic acid analog |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2972344B2 (ja) | 1999-11-08 |
| US5717083A (en) | 1998-02-10 |
| CA2184005A1 (en) | 1995-08-31 |
| US5637684A (en) | 1997-06-10 |
| DE69528362D1 (de) | 2002-10-31 |
| EP0751948B1 (en) | 2002-09-25 |
| AU1969195A (en) | 1995-09-11 |
| ATE224908T1 (de) | 2002-10-15 |
| WO1995023160A1 (en) | 1995-08-31 |
| AU677150B2 (en) | 1997-04-10 |
| CA2184005C (en) | 2000-01-25 |
| EP0751948A1 (en) | 1997-01-08 |
| EP0751948A4 (en) | 1997-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH09509663A (ja) | 新規ホスホルアミデートおよびホスホロチオアミデートオリゴマー化合物 | |
| Uhlmann et al. | Antisense oligonucleotides: a new therapeutic principle | |
| US6593466B1 (en) | Guanidinium functionalized nucleotides and precursors thereof | |
| RU2572826C2 (ru) | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот | |
| JP3831407B2 (ja) | メチルホスホン酸エステル、その製造方法およびその使用 | |
| US5714606A (en) | Pyrrolidine-containing monomers and oligomers | |
| US5886177A (en) | Phosphate linked oligomers | |
| US20030036066A1 (en) | Linker phosphoramidites for oligonucleotide synthesis | |
| JPH09511250A (ja) | 核酸治療に有用な修飾オリゴヌクレオチド及び中間体 | |
| JPH07233188A (ja) | 新規ヌクレオシドホスホルアミダイトおよびその製造方法 | |
| CA2330192A1 (en) | Activators for oligonucleotide synthesis | |
| JPH02169598A (ja) | 新規なハイドロゲンホスホノジチオエート組成物 | |
| US6649750B1 (en) | Process for the preparation of oligonucleotide compounds | |
| JP3072127B2 (ja) | モノマージオールおよびそれらから形成されるホスフェート結合オリゴマー | |
| US5571937A (en) | Complementary DNA and toxins | |
| US6184389B1 (en) | Combinatorial libraries having aminodiol monomer subunits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20070827 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080827 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090827 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100827 Year of fee payment: 11 |
|
| LAPS | Cancellation because of no payment of annual fees | ||
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |